Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjeev Redkar

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Pharmaceutical Sciences|March 5, 2011
Expect the unexpected-screen your screensHarish Ravivarapu, Sanjeev Redkar
AAPS Pharmscitech|October 6, 2007
Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeationRavichandran Mahalingam, Harish Ravivarapu, Sanjeev Redkar, et al.
Blood|June 2, 2011
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemiaLisa S Chen, Sanjeev Redkar, Pietro Taverna, et al.
Blood|September 8, 2009
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cellsLisa S Chen, Sanjeev Redkar, David Bearss, et al.
Bioorganic & Medicinal Chemistry|May 4, 2013
Structure-activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1Swarna A Gamage, Darby G Brooke, Sanjeev Redkar, et al.
JCO Precision Oncology|June 8, 2022
MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic SchwannomaJenny J Li, Xiaoling Zhang, Neil Sankar, et al.
Cancer Research|July 10, 2007
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotidesChristine B Yoo, Shinwu Jeong, Gerda Egger, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2012
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumorsRaoul Tibes, Gil Fine, Gavin Choy, et al.
Cancer Research|December 15, 2023
Retraction: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its DegradationJharna Datta, Kalpana Ghoshal, William A Denny, et al.
Cancer Research|May 7, 2009
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradationJharna Datta, Kalpana Ghoshal, William A Denny, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Pharmaceutical Sciences|March 5, 2011
Expect the unexpected-screen your screensHarish Ravivarapu, Sanjeev Redkar
AAPS Pharmscitech|October 6, 2007
Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeationRavichandran Mahalingam, Harish Ravivarapu, Sanjeev Redkar, et al.
Blood|June 2, 2011
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemiaLisa S Chen, Sanjeev Redkar, Pietro Taverna, et al.
Blood|September 8, 2009
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cellsLisa S Chen, Sanjeev Redkar, David Bearss, et al.
Bioorganic & Medicinal Chemistry|May 4, 2013
Structure-activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1Swarna A Gamage, Darby G Brooke, Sanjeev Redkar, et al.
JCO Precision Oncology|June 8, 2022
MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic SchwannomaJenny J Li, Xiaoling Zhang, Neil Sankar, et al.
Cancer Research|July 10, 2007
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotidesChristine B Yoo, Shinwu Jeong, Gerda Egger, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2012
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumorsRaoul Tibes, Gil Fine, Gavin Choy, et al.
Cancer Research|December 15, 2023
Retraction: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its DegradationJharna Datta, Kalpana Ghoshal, William A Denny, et al.
Cancer Research|May 7, 2009
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradationJharna Datta, Kalpana Ghoshal, William A Denny, et al.
Pageof 2